具有分子驱动改变的非小细胞肺癌的免疫检查点抑制反应。
Response to Checkpoint Inhibition in Non-Small Cell Lung Cancer with Molecular Driver Alterations.
机构信息
Division of Respiratory Medicine and Thoracic Oncology, Department of Internal Medicine V, Thoracic Oncology Center Munich, University of Munich (LMU), Munich, Germany,
Division of Respiratory Medicine and Thoracic Oncology, Department of Internal Medicine V, Thoracic Oncology Center Munich, University of Munich (LMU), Munich, Germany.
出版信息
Oncol Res Treat. 2020;43(6):289-298. doi: 10.1159/000506842. Epub 2020 Apr 8.
AIMS
Non-small cell lung cancer (NSCLC) patients with EGFR mutations do not respond well to checkpoint inhibitors. However, little is known about the activity of immunotherapy in NSCLC with other driver mutations. The increasing use of next-generation sequencing (NGS) leads to molecular findings that face the clinician with problems while choosing the best treatment. This study aims at analyzing response of NSCLC with driver mutations to immunotherapy.
PATIENTS AND METHODS
We retrospectively included 84 NSCLC patients diagnosed and treated at 2 German tertiary-care lung cancer centers using NGS and treatment with immunotherapy. Response to immunotherapy was analyzed in correlation to molecular findings.
RESULTS
51 patients harbored at least 1 driver mutation. PIK3CA, EGFR, and STK11 mutations did not respond to immunotherapy. KRAS, TP53, and MET exon 14 skipping mutations responded well. One patient with NF-1 mutation showed durable response.
CONCLUSIONS
Molecular testing may be of use in guiding treatment decision making in NSCLC.
目的
具有 EGFR 突变的非小细胞肺癌 (NSCLC) 患者对检查点抑制剂反应不佳。然而，对于具有其他驱动突变的 NSCLC 中免疫治疗的活性知之甚少。下一代测序 (NGS) 的广泛应用导致分子发现，这给临床医生在选择最佳治疗方法时带来了问题。本研究旨在分析具有驱动突变的 NSCLC 对免疫治疗的反应。
患者和方法
我们回顾性纳入了 84 名在德国 2 家三级肺癌中心使用 NGS 诊断和治疗并接受免疫治疗的 NSCLC 患者。分析了免疫治疗的反应与分子发现的相关性。
结果
51 名患者至少携带 1 种驱动突变。PIK3CA、EGFR 和 STK11 突变对免疫治疗无反应。KRAS、TP53 和 MET 外显子 14 跳跃突变反应良好。1 名 NF-1 突变患者表现出持久的反应。
结论
分子检测可能有助于指导 NSCLC 的治疗决策。
Zotero 插件